|Mr. Dan W. Gladney||Chairman, Pres & CEO||651.03k||N/A||1953|
|Mr. Scott P. Youngstrom||CFO, Sr. VP of Fin. & Sec.||410.77k||N/A||1960|
|Mr. Naqeeb A. Ansari||VP of Worldwide Sales||327.46k||N/A||1961|
|Dr. Mark B. Knudson Ph.D.||Co-Founder and Special Advisor to the CEO||N/A||N/A||1949|
|Dr. Katherine S. Tweden Ph.D.||Co-Founder||N/A||N/A||1961|
ReShape Lifesciences Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology, vBloc Therapy is designed to intermittently block the vagus nerve using electrical impulses. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; and ReShape Balloon system that uses balloon technology designed to take up room in the stomach to enable people lose weight. Its product portfolio also comprises ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.
ReShape Lifesciences Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.